Comprehensive genetic assessment of the estrogen receptor 1 (ESR1) locus identifies a risk region for endometrial cancer


1 Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
2 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
3 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.
4 Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW, 2305, Australia.
5 Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, 2305, Australia.
6 Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, 2305, Australia.
7 Centre for Information Based Medicine, University of Newcastle, NSW, 2308, Australia.
8 School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, 2308, Australia.
9 School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, 2308, Australia.
10 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
11 Department of Clinical Genetics, St George’s Hospital Medical School, London, SW17 0RE, UK.
12 University of California at Los Angeles, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
13 Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, 91054, Germany.
14 Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen- Nuremberg, Erlangen, 91054, Germany.
15 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
16 Department of Gynaecology, Jena University Hospital - Friedrich Schiller University, Jena, 07743, Germany.
17 Hannover Medical School, Clinics of Gynaecology and Obstetrics, Hannover, 30625, Germany.
18 Hannover Medical School, Gynaecology Research Unit, Hannover, 30625, Germany.
19 Vesalius Research Center, Leuven, 3000, Belgium.
20 Laboratory for Translational Genetics, Department of Oncology, University Hospitals Leuven, Leuven, 3000, Belgium.
21 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals, KU Leuven - University of Leuven, 3000, Belgium.
22 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.
23 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
24 Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
25 Centre for Cancerbiomarkers, Department of Clinical Science, The University of Bergen, 5020, Norway.
Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, 5021, Norway.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, SE-171 77, Sweden.
Department of Cancer Epidemiology, Division of Population Sciences, Moffitt Cancer Center, Tampa, FL, 33612, USA.
Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Vic, 3010, Australia.
Peter MacCallum Cancer Center, The University of Melbourne, Melbourne, 3002, Australia.
London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Division of Genetics and Epidemiology, Institute of Cancer Research, London, SM2 5NG, UK.
Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, 69120, Germany.
Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, 69120, Germany.
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
Department of Obstetrics and Gynecology, Division of Tumor Genetics, Technical University of Munich, Munich, 80333, Germany.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 70376, Germany.
University of Tübingen, Tübingen, 72074, Germany
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Vic, 3004, Australia.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, 3004, Australia.
Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, 0310, Norway.
The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 0316, Norway.
Department of Clinical Molecular Oncology, Division of Medicine, Akershus University Hospital, Lørenskog, 1478, Norway.
Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, S10 2RX, UK.

* To whom correspondence should be addressed. Tel: +61 7336 20371; Fax: +61 7336 20111; Email: Amanda.Spurdle@qimrberghofer.edu.au
SUPPLEMENTARY INFORMATION

Contents
A. ECAC Study Collaborators (for case samples): ................................................................. 4
B. BCAC and OCAC Study Collaborators (for control samples): ....................................... 4
C. Supplementary Acknowledgements.................................................................................. 5
A. ECAC Study Collaborators (for case samples):

The ANECS Group comprises:


CHIBCHA (study of hereditary cancer in Europe and Latin America) collaborators include:

Ma. Magdalena Echeverry de Polanco, Mabel Elena Bohórquez, Rodrigo Prieto, Angel Criollo, Carolina Ramírez, Ana Patricia Estrada, Jhon Jairo Suárez (Grupo de Citogenética Filogenia y Evolución de Poblaciones, Universidad del Tolima, Colombia); Augusto Rojas Martínez (Center for Research and Development in Health Sciences, Universidad Autónoma de Nuevo León, Monterrey, Mexico); Silvia Rogatto, Samuel Aguiar Jnr, Ericka Maria Monteiro Santos (Department of Urology, School of Medicine, UNESP - São Paulo State University, Botucatu, Brazil); Monica Sans, Valentina Colistro, Pedro C. Hidalgo, Patricia Mut (Department of Biological Anthropology, College of Humanities and Social Sciences, University of the Republic, Magallanes, Montevideo, Uruguay); Angel Carracedo, Clara Ruiz Ponte, Ines Quintela Garcia (Fundacion Publica Galega de Medicina Xenomica, CIBERER, Genomic Medicine Group-University of Santiago de Compostela, Hospital Clínico, Santiago de Compostela, Galicia, Spain); Sergi Castellvi-Bel (Department of Gastroenterology, Institut de Malalties Digestives i Metabòliques, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain); Manuel Teixeira (Department of Genetics, Portuguese Oncology Institute, Rua Dr, António Bernardino de Almeida, Porto, Portugal).

NECS collaborators include:

Ute Hamann and Michael Gilbert.

The NSECG Group comprises:


REDOCAS investigators include:

Annika Lindblom, Gerasimos Tzortzatos, Miriam Mints, Emma Tham, Ofra Castro, Kristina Gemzell-Danielsson.

SEARCH collaborators include:

Helen Baker, Caroline Baynes, Don Conroy, Bridget Curzon, Patricia Harrington, Sue Irvine, Craig Luccarini, Rebecca Mayes, Hannah Munday, Barbara Perkins, Daisy Pharoah, Radka Platte, Anne Stafford and Judy West.

B. BCAC and OCAC Study Collaborators (for control samples):

The Australian Ovarian Cancer Study Group comprises:

Davy, MK Oehler, C Hall, T Dodd, T Healy, K Pittman, D Henderson, J Miller, J Pierdes, A Acham; 
TAS- P Blomfield, D Challis, R McIntosh, A Parker; VIC - B Brown, R Rome, D Allen, P Grant, S Hyde, 
R Laurie M Robbie, D Healy, T Jobling, T Manolitsas, J McNealage, P Rogers, B Susil, E Sumithran, I 
Simpson, I Haviv, K Phillips, D Rischin, S Fox, D Johnson, S Lade, P Waring, M Loughrey, N 
O’Callaghan, B Murray, L Mileshkin, P Allan; V Billson, J Pyman, D Neesham, M Quinn, A Hamilton, 
C Underhill, R Bell, LF Ng, R Blum, V Ganju; WA- I Hammond, A McCartney (deceased), C Stewart, 
Y Leung, M Buck, N Zeps (WARTN); AOCS Management Group- DDL Bowtell, AC Green, G 
Chenevix-Trench, A deFazio, D Gertig, PM Webb.

**BSUCH collaborator:** Peter Bugert.

**ESTHER collaborators:** Volker Arndt, Heiko Müller, Christa Stegmaier.

**GENICA Network collaborators:** Wing-Yee Lo, Christina Justenhoven, Ute Hamann, Thomas 
Brüning, Beate Pesch, Yon-Dschun Ko, Sylvia Rabstein, Anne Lotz, Christina Baisch, Hans-Peter 
Fischer, Volker Harth.

### C. Supplementary Acknowledgements

The authors thank the many individuals who participated in this study and the numerous institutions 
and their staff who have supported recruitment.

ANECS thanks members of the Molecular Cancer Epidemiology and Cancer Genetic laboratories at 
QIMR Berghofer Medical Research Institute for technical assistance, and the ANECS research team 
for assistance with the collection of risk factor information and blood samples. ANECS also gratefully 
acknowledges the cooperation of the following institutions: NSW: John Hunter Hospital, Liverpool 
Hospital, Mater Misericordiae Hospital (Sydney), Mater Misericordiae Hospital (Newcastle), Newcastle 
Private Hospital, North Shore Private Hospital, Royal Hospital for Women, Royal Prince Alfred 
Hospital, Royal North Shore Hospital, Royal Prince Alfred Hospital, St George Hospital; Westmead 
Hospital, Westmead Private Hospital; Qld: Brisbane Private Hospital, Greenslopes Hospital, Mater 
Misericordiae Hospitals, Royal Brisbane and Women’s Hospital, Wesley Hospital, Queensland Cancer 
Registry; SA: Adelaide Pathology Partners, Burnside Hospital, Calvary Hospital, Flinders Medical 
Centre, Queen Elizabeth Hospital, Royal Adelaide Hospital, South Australian Cancer Registry; Tas: 
Launceston Hospital, North West Regional Hospitals, Royal Hobart Hospital; Vic: Freemasons 
Hospital, Melbourne Pathology Services, Mercy Hospital for Women, Royal Women's Hospital, 
Victorian Cancer Registry; WA: King Edward Memorial Hospital, St John of God Hospitals Subiaco & 
Murdoch, Western Australian Cancer Registry.

SEARCH thanks the SEARCH research team for recruitment, and also acknowledges the assistance 
of the Eastern Cancer Registration and Information Centre for subject recruitment.

BECS thanks Reiner Strick, Silke Landrith and Sonja Oeser for their logistic support during the study.

CAHRES (formerly known as SASBAC) thanks Li Yuqing from the Genome Institute of Singapore for 
contributions to this study, and also acknowledges previous input to SASBAC resource creation by 
Anna Christenssson, Boel Bissmarck, Kirsimari Aaltonen, Karl von Smitten, Nina Puolakka, Christer 
Halldén, Lim Siew Lan and Irene Chen, Lena U. Rosenberg, Mattias Hammarström, and Eija Flygare.

HJECS thanks Wen Zheng, Hermann Hertel, and Tjoung-Won Park-Simon at Hannover Medical 
School for their contribution to sample recruitment.

LES gratefully acknowledges Helena Soenen, Gilian Peuteman and Dominiek Smeets for their 
technical assistance.

MECS thanks Tom Sellers, Catherine Phelan, Andrew Berchuck, and Kimberly Kalli, Amanda von 
Bismarck, Luisa Freyer and Lisa Rogmann.

MoMaTEC thanks Brit Edvardsen, Ingrid Bergo and Mari Kylsø Halle for technical assistance and 
Inger Marie Aksnes and Tor Audun Hervig at the Blood bank, Haukeland University Hospital for
assistance with control recruitment.

NECS thanks staff at the University of Newcastle and the Hunter Medical Research Institute.

NSEC Gy thank Ella Barclay and Lynn Martin for their contribution, and acknowledge the invaluable help of the National Cancer Research Network with the collection of study participants.

QIMR Berghofer thanks Margie Wright, Lisa Bowdler, Sara Smith, Megan Campbell and Scott Gordon for control sample collection and data processing, Kerenaftali Klein for statistical advice and Brendan Ryan for assistance with the figures.

REDOCAS thanks Berith Wejderot, Sigrid Sahlen, Tao Liu, Margareta Ström, Maria Karlsson, and Birgitta Byström for their contribution to the study.

BSUCH thanks the Medical Faculty, Mannheim, the Diemtmar Hopp Foundation and the German Cancer Research Center.

MCCS was made possible by the contribution of many people, including the original investigators and the diligent team who recruited the participants and who continue working on follow up. We would like to express our gratitude to the many thousands of Melbourne residents who continue to participate in the study.

The UKBGS thank Breakthrough Breast Cancer and the Institute of Cancer Research for support and funding, and the Study participants, Study staff, and the doctors, nurses and other health care staff and data providers who have contributed to the Study. The ICR acknowledges NHS funding to the NIHR Biomedical Research Centre.

In addition, the iCOGS study would not have been possible without the contributions of: Andrew Berchuck (OCAC), Rosalind A. Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Cancer Genetic Epidemiology Laboratory (Cambridge), Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility.